2.53
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.69
Offen:
$2.571
24-Stunden-Volumen:
12.48M
Relative Volume:
0.81
Marktkapitalisierung:
$915.49M
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-440.22M
KGV:
-1.515
EPS:
-1.67
Netto-Cashflow:
$-400.48M
1W Leistung:
+1.20%
1M Leistung:
-19.17%
6M Leistung:
-52.62%
1J Leistung:
-78.69%
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IOVA
Iovance Biotherapeutics Inc
|
2.53 | 904.63M | 32.77M | -440.22M | -400.48M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
2025-05-16 | Herabstufung | UBS | Buy → Neutral |
2025-05-12 | Herabstufung | Truist | Buy → Hold |
2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
2024-10-24 | Eingeleitet | UBS | Buy |
2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
2023-11-20 | Eingeleitet | Goldman | Buy |
2023-09-18 | Bestätigt | Barclays | Overweight |
2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
2022-10-31 | Eingeleitet | Guggenheim | Neutral |
2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
2022-01-28 | Hochstufung | Stifel | Hold → Buy |
2021-12-07 | Fortgesetzt | Cowen | Outperform |
2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2021-05-19 | Herabstufung | Stifel | Buy → Hold |
2021-05-03 | Eingeleitet | Truist | Buy |
2021-04-16 | Eingeleitet | Goldman | Buy |
2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-04-22 | Eingeleitet | Mizuho | Buy |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
2020-02-26 | Bestätigt | Oppenheimer | Outperform |
2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
2019-10-01 | Eingeleitet | Stifel | Buy |
2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Around the Helix: Cell and Gene Therapy Company Updates – August 20, 2025 - CGTLive®
Iovance Biotherapeutics Gains Health Canada Approval - MSN
Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) Over Potential Securities Fraud Allegations - 28/22 News
Iovance Biotherapeutics’ TIL Therapy Lifileucel Approved for Advanced Melanoma in Canada - CGTLive®
Unexpected Surge: Analyzing Iovance’s Performance - StocksToTrade
Why Iovance Biotherapeutics Stock Was Climbing Today - Mitrade
Why Iovance Biotherapeutics Stock Was Climbing Today - The Motley Fool
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ - Stocktwits
Iovance Stock Soars 21.2% on Amtagvi Approval - AInvest
Iovance gets conditional Health Canada approval for Amtagvi - MSN
Health Canada approves Iovance’s Amtagvi for advanced melanoma By Investing.com - Investing.com India
Iovance Says Amtagvi Gets Health Canada Clearance for Advanced Melanoma - MarketScreener
Health Canada approves Iovance’s Amtagvi for advanced melanoma - Investing.com
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma - The Manila Times
Iovance Biotherapeutics Receives Health Canada Approval for Amtagvi® T Cell Therapy for Advanced Melanoma - Quiver Quantitative
Iovance's Amtagvi receives Health Canada approval for advanced melanoma - MarketScreener
First-Ever T Cell Therapy for Solid Tumors: Iovance's Amtagvi Gets Historic Canada Approval - Stock Titan
Wells Fargo Lowers Price Target for Iovance Biotherapeutics (IOVA) Amid Mixed Q2 Results: Is Amtagvi's Growth Enough to Justify the Downgrade? - AInvest
Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth - Yahoo Finance
Is Iovance Biotherapeutics Inc. a momentum stock2025 Stock Rankings & Safe Capital Growth Plans - thegnnews.com
Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data - MSN
Iovance Biotherapeutics shares rise 2.04% premarket as private investment in oncology ventures surges. - AInvest
Iovance Biotherapeutics’ SWOT analysis: navigating challenges in cancer immunotherapy stock - Investing.com
Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - MSN
Iovance Biotherapeutics shares rise 3.27% intraday as private investment in oncology ventures surges. - AInvest
Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million - Yahoo Finance
Iovance Biotherapeutics' Earnings Call Highlights Growth, Revenue Up 22% to $60M - AInvest
Iovance Biotherapeutics’ Earnings Call Highlights Growth - TipRanks
Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight - The Malaysian Reserve
Iovance Soars on Amtagvi Success: What’s Next? - StocksToTrade
Iovance Biotherapeutics Surges on Promising Study Outcomes - timothysykes.com
AI Tools Suggest Iovance Biotherapeutics Inc. May Outperform This WeekBuy Alerts With Low Risk Confirmation Noted - 선데이타임즈
Published on: 2025-08-12 06:23:53 - beatles.ru
Iovance Biotherapeutics' Strategic Turnaround and Regulatory Hurdles: Is the Biotech Buyable at a 64% YTD Decline? - AInvest
Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Second-Quarter Results - 富途牛牛
Iovance Biotherapeutics' Q2 2025 Earnings Miss and Strategic Restructuring: A Turning Point or Deepening Crisis? - AInvest
Iovance Biotherapeutics Q2 Revenue Misses Estimates, Shares Plummet - AInvest
Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Call Transcript - Insider Monkey
Measuring Iovance Biotherapeutics Inc.’s beta against major indicesAlgorithmic Prediction of Market Breakouts - Newser
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
How to escape a deep drawdown in Iovance Biotherapeutics Inc.Free Step-by-Step Trade Signal Implementation - Newser
Reversal indicators forming on Iovance Biotherapeutics Inc. stockDownside Control Plan With Support Analysis - Newser
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - Mitrade
Key resistance and support levels for Iovance Biotherapeutics Inc.Free Capital Growth With Controlled Risk Picks - Newser
How to escape a deep drawdown in Iovance Biotherapeutics IncPredictive Screener for Daily Trade Watch - Newser
Is Iovance Biotherapeutics Inc. stock bottoming outReal Time Trade Execution Alert Plan - Newser
Real time social sentiment graph for Iovance Biotherapeutics Inc.Trading Volume Anomaly Summary and Insight - Newser
Why Iovance Biotherapeutics Stock Plummeted Today - AOL.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Iovance Biotherapeutics Inc-Aktie (IOVA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
Vogt Frederick G | Interim CEO & General Counsel |
May 14 '25 |
Buy |
1.69 |
25,000 |
42,250 |
374,646 |
Puri Raj K. | Chief Regulatory Officer |
Mar 14 '25 |
Option Exercise |
0.00 |
8,334 |
0 |
203,761 |
Bellemin Jean-Marc | Chief Financial Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
58,590 |
0 |
87,938 |
BILINSKY IGOR | Chief Operating Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
62,106 |
0 |
120,880 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):